Hormonal
Reduced glucose flux into adipose tissue (due to GLUT4 downregulation or knockout) triggers the secretion of Retinol-Binding Protein 4 (RBP4), which acts as a signaling molecule to induce systemic insulin resistance in muscle and liver.
In states of insulin resistance, fat cells may stop taking up glucose efficiently and instead release a protein called RBP4 that tells your muscles and liver to resist insulin. This is a biological signal, not just a passive storage issue. Managing this involves improving overall metabolic flexibility, though the paper highlights this as a pathologic mechanism in diabetes rather than a direct lifestyle intervention protocol.
We recently described a new adipokine, retinol-binding protein 4 (RBP4), which contributes to the insulin resistance that develops in the AG4KO mouse model... pharmacologically or genetically increasing serum RBP4 levels impairs insulin signaling in muscle and increases phosphoenolpyruvate by inducing cytosolic phosphoenolpyruvate carboxykinase (PEPCK) expression in liver, resulting in systemic insulin resistance.
Why this rating
Based on transgenic mouse models (AG4KO) and correlation with human insulin-resistant states, though the exact mechanism of flux-to-RBP4 translation is noted as under investigation.
Source
Glucose transport and sensing in the maintenance of glucose homeostasis and metabolic harmony
Mark A. Herman · Journal of Clinical Investigation · 2006
DOI 10.1172/jci29027
More from this paper
- Glucose and its metabolites (e.g., lactate, alanine, TCA intermediates) act as signaling molecules that communicate the metabolic status of peripheral tissues (muscle, adipose) to other organs (liver, hypothalamus) to maintain glucose homeostasis.Strong
- Muscle-specific knockout of GLUT4 causes secondary insulin resistance in liver and adipose tissue, demonstrating that muscle glucose transport is critical for systemic insulin sensitivity.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →